Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2001-12-13
pubmed:abstractText
New effective therapies are needed to improve the outcome of patients with advanced non-small-cell lung cancer (NSCLC). The aim of this study was to assess the response rate and survival obtained with a sequential regimen of chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1369-74
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:11762806-Adult, pubmed-meshheading:11762806-Aged, pubmed-meshheading:11762806-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11762806-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11762806-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:11762806-Cisplatin, pubmed-meshheading:11762806-Deoxycytidine, pubmed-meshheading:11762806-Disease Progression, pubmed-meshheading:11762806-Disease-Free Survival, pubmed-meshheading:11762806-Drug Administration Schedule, pubmed-meshheading:11762806-Female, pubmed-meshheading:11762806-Humans, pubmed-meshheading:11762806-Infusions, Intravenous, pubmed-meshheading:11762806-Lung Neoplasms, pubmed-meshheading:11762806-Male, pubmed-meshheading:11762806-Middle Aged, pubmed-meshheading:11762806-Neutropenia, pubmed-meshheading:11762806-Paclitaxel, pubmed-meshheading:11762806-Peripheral Nervous System Diseases, pubmed-meshheading:11762806-Treatment Outcome, pubmed-meshheading:11762806-Vinblastine
pubmed:year
2001
pubmed:articleTitle
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
pubmed:affiliation
Servicio de Oncología Médica, Hospitals La Paz, Madrid, Spain. oncopaz@ene.es
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II